233 related articles for article (PubMed ID: 18945356)
21. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
22. Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests.
Bánkfalvi A; Boecker W; Reiner A
Int J Oncol; 2004 Oct; 25(4):929-35. PubMed ID: 15375542
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
[TBL] [Abstract][Full Text] [Related]
25. Double-target in situ hybridization in brightfield microscopy.
Kerstens HM; Poddighe PJ; Hanselaar AG
J Histochem Cytochem; 1994 Aug; 42(8):1071-7. PubMed ID: 8027526
[TBL] [Abstract][Full Text] [Related]
26. Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study.
van der Logt EM; Kuperus DA; van Setten JW; van den Heuvel MC; Boers JE; Schuuring E; Kibbelaar RE
PLoS One; 2015; 10(4):e0123201. PubMed ID: 25844540
[TBL] [Abstract][Full Text] [Related]
27. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
[TBL] [Abstract][Full Text] [Related]
28. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
[TBL] [Abstract][Full Text] [Related]
29. A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay.
Bartlett JM; Campbell FM; Ibrahim M; O'Grady A; Kay E; Faulkes C; Collins N; Starczynski J; Morgan JM; Jasani B; Miller K
Am J Clin Pathol; 2011 Jan; 135(1):157-62. PubMed ID: 21173138
[TBL] [Abstract][Full Text] [Related]
30. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
[TBL] [Abstract][Full Text] [Related]
31. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
Ying JM; Liu XY; Guo L; Xie YQ; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
[TBL] [Abstract][Full Text] [Related]
33. Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study.
Tubbs RR; Pettay JD; Swain E; Roche PC; Powell W; Hicks DG; Grogan T
Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):436-40. PubMed ID: 17122642
[TBL] [Abstract][Full Text] [Related]
34. Validation of Dual-Color Dual In Situ Hybridization for HER2/neu Gene in Breast Cancer.
Rathi A; Sahay A; Shet TM; Patil A; Desai SB
Arch Pathol Lab Med; 2024 Apr; 148(4):453-460. PubMed ID: 37490416
[TBL] [Abstract][Full Text] [Related]
35. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
36. Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment.
Kosa C; Kardos L; Kovacs J; Szollosi Z
Pathol Res Pract; 2013 Mar; 209(3):147-50. PubMed ID: 23419693
[TBL] [Abstract][Full Text] [Related]
37. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.
Lee Y; Ryu Y; Jeong H; Chang H; Kim Y; Kim A
Arch Med Res; 2012 Feb; 43(2):139-44. PubMed ID: 22475781
[TBL] [Abstract][Full Text] [Related]
39. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
Pu X; Shi J; Li Z; Feng A; Ye Q
Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]